This 30-minute CCCEP/OPQ-accredited eCME program offers pharmacists an evidence-based overview of the evolving role of dual orexin receptor antagonists (DORAs) in chronic insomnia management. Designed with a focus on functional outcomes and patient-centered care, the program explores how this targeted class of therapies is shifting the approach to chronic insomnia management—regulating wakefulness rather than inducing sedation.
Pharmacists will gain practical insights on initiating these targeted therapies, counseling patients on treatment expectations, and supporting smooth transitions from traditional sleep medications. Clinical considerations such as daytime functioning, safety, and adherence will be emphasized to help optimize long-term outcomes.
This program has received financial support from Idorsia Pharmaceuticals Ltd in the form of an unrestricted educational grant.
